Biologics Coverage

Therapeutic Proteins Market Definition And Segments

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins market are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market covered in this report is segmented – 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics 3) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications The therapeutic proteins market size has grown rapidly in recent years. It will grow from $140.96 billion in 2023 to $158.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to advances in protein engineering, expansion into chronic diseases, advent of immunotherapy, development of recombinant DNA technology, targeted cancer therapies. The therapeutic proteins market size is expected to see rapid growth in the next few years. It will grow to $257.4 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to regulatory adaptations, enhanced delivery systems, gene editing integration, biobetters development, immunotherapy evolution. Major trends in the forecast period include regulatory framework enhancements, improved delivery systems, biotechnology advancements, personalized medicine, monoclonal antibodies dominance.

Technological Advancements Fueling The Growth Of The Therapeutic Proteins Market

The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesized chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic proteins drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic proteins drugs developed using protein engineering technologies and approved by the FDA in the past five years.

Rising Prevalence Of Chronic Diseases, Including Diabetes, Fuels Growth Of Therapeutic Protein Market

The increasing prevalence of chronic diseases, such as diabetes, is expected to propel the growth of the therapeutic protein market going forward. Chronic diseases refer to ailments that last for a year or longer, impede everyday activities, require continuing medical care, or both. Diabetes is a chronic health condition in which the body doesn’t make enough insulin or doesn’t use insulin properly. In diabetes, several protein therapeutics, such as insulin and GLP-1 receptor agonists, are used to regulate blood sugar levels and manage the disease. They stimulate the release of insulin in response to elevated blood glucose levels and also reduce the production of glucagon, another hormone that raises blood sugar. For instance, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20–79 years old) in 2021, and it is predicted that the number is going to climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the increasing prevalence of chronic diseases, such as diabetes, is driving the growth of the therapeutic protein market. Major companies operating in the therapeutic proteins market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Co., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring LLC, Chugai Pharmaceutical Co. Ltd., Biogen Inc., Kyowa Kirin Co. Ltd., Oramed Pharmaceuticals Inc., Sandoz International GmbH, Hualan Biological Engineering Inc., Genentech Inc., ProBiogen AG, Diasome Pharmaceuticals Inc., Generex Biotechnology Corp., GeneScience Pharmaceuticals Co. Ltd.

Growing Number Of Biosimilar Drugs Impede Therapeutic Protein Market Growth

Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic proteins market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market. For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSY (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins market.

Rising Approvals Of Monoclonal Antibody Drugs In Protein Therapeutics

Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies. In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders.

Expanding Production Capacities With Media Systems In The Therapeutic Protein Market

Major companies operating in the therapeutic protein market are focused on introducing media systems to meet growing demand for therapeutic proteins and gain a competitive edge in the market. The media system for therapeutic proteins is a production system designed to optimize the production of therapeutic monoclonal antibodies. For instance, in July 2023, Lonza Group AG, a Switzerland-based pharmaceutical manufacturing company, launched the TheraPRO CHO (Chinese Hamster Ovary) Media System, a new cell culture platform to improve productivity and quality in therapeutic protein manufacture. The two-part, chemically specified production technique is simple to use and makes media preparation easier. It has full scalability and is supported by technical professionals with in-depth troubleshooting knowledge.

Eli Lilly And Company's Acquisition Of Protomer Technologies

Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021. Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specializes in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. North America was the largest region in the therapeutic proteins market in 2023. The regions covered in the therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. The therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cell Therapy Market Definition And Segments

Cell therapy refers to the replacement or repair of damaged tissue and/or cells through the transplantation of human cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. It is a form of treatment wherein a patient receives live cells via injection, grafting, or implant in order to produce a therapeutic result. The main techniques used in cell therapy are stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also known as regenerative medicine, uses stem cells or their derivatives to stimulate the healing response of sick, defective, or wounded tissue. The different types of therapies include allogeneic therapies, and autologous therapies and are used in various applications such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and others. The cell therapy market covered in this report is segmented – 1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy 2) By Therapy Type: Allogeneic Therapies, Autologous Therapies 3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications The cell therapy market size has grown rapidly in recent years. It will grow from $12.58 billion in 2023 to $14.72 billion in 2024 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to early research and discoveries, regulatory milestones, clinical trials and studies, early adopters and pioneering companies, market acceptance and perception. The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $25.86 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to ethical and societal considerations, investment and funding trends, consumer/patient demand, healthcare infrastructure, rapid innovation cycles. Major trends in the forecast period include personalized medicine, emerging targeted treatments, gene editing technologies, stem cell research expansion, immunotherapy advancements, microenvironment manipulation.

The Soaring Prevalence Of Chronic Diseases Fuels Expansion In The Cell Therapy Market

The rising prevalence of chronic diseases aided the expansion of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more, requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Disease Control and Prevention report in 2021, due to poor nutrition and a lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease, and 4 in 10 have two or more diseases. In December 2021, according to the International Diabetes Federation, a Belgium based health organization, about 537 million people (20–79 years old) will have diabetes. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. Nearly one-half of all diabetics (240 million) go undiagnosed, and three out of every four diabetic adults live in low- and middle-income countries. According to the Parkinson’s Foundation, in 2021, approximately 60,000 Americans will be diagnosed with PD each year, and 10 million individuals worldwide will suffer from this disease. After Alzheimer's, it is the second most prevalent neurological disease. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the cell therapy market.

Surge In Investment Fueling The Growth Of The Cell Therapy Market

The rising investment is expected to propel the growth of the cell therapy market going forward. Investment in cell therapy refers to the allocation of financial resources, capital, or funding to support the research, development, manufacturing, and commercialization of cell-based therapies. Investment in cell therapy is being used to support the research and development of new cell therapy products and technologies, as well as to conduct clinical trials to evaluate these products and technologies, which will boost and improve cell therapies. For instance, in February 2022, according to reports published by Cell & Gene, a US-based life sciences company, cell therapy has grown significantly, reflecting an astonishing increase from $362 million in investment in 2020 to nearly $68 billion in 2021. Therefore, rising investment is driving the growth of the cell therapy market. Major companies operating in the cell therapy market report are Celgene Corporation, JCR Pharmaceuticals Co. Ltd., Baxter Healthcare Corporation, Nipro Corp., Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., Arteriocyte Medical Systems Inc., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics PLC, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Tego Science Inc., Athersys Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, AVROBIO Inc., Cellular Biomedicine Group Inc., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Charles River Laboratories International Inc., Lonza Group Ltd., Catalent Inc.

The Challenge Of High Costs Impeding The Growth Of The Cell Therapy Industry

The high cost of cell therapy has hindered the growth of the cell therapy industry. Cell therapies have become a common choice of treatment in recent years as people look for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost around $1,000, and more specialized procedures can cost up to $100,000 depending on the condition. In the United States, the average cost of stem cell therapy in 2020 is expected to range between $4,000 and $8,000 per patient. Therefore, the high cost of cell therapy restrains the growth of the cell therapy market.

Strategic Partnerships And Acquisitions Drive Expansion In The Cell Therapy Market

Key market players are strategically partnering and collaborating to expand the company's product portfolio and geographical presence. For instance, in October 2021, Takeda, a Japan-based pharmaceutical company, acquired Gamma Delta Therapeutics, a US-based company that offers cell therapies, to speed up the development of allogeneic T cell therapies for solid tumors. Furthermore, in June 2021, Charles River Laboratories, a US-based pharmaceutical company, acquired Vigene Biosciences Inc., a US-based biotech company. With this acquisition, Charles River aims to expand its gene therapy capabilities, establish an end-to-end gene therapy solution in the US, and accelerate its long-term revenue and earnings growth potential.

Genentech's Strategic Partnership With Arsenal Biosciences Aims To Advance Next-Generation Cell Therapies For Solid Tumors

Major companies operating in the cell therapy market are adopting a strategic partnership approach to provide innovative and effective therapies to patients. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in September 2022, Genentech Inc., a US biotechnology corporation, partnered with Arsenal Biosciences, Inc., a US-based programmable cell therapy company. With this partnership, they aim to accelerate the development of next-generation cell therapy products. It could lead to the development of new and more effective cell therapies for solid tumors, which would be a major breakthrough for cancer patients. And committed to investing in new technologies and bringing new and innovative treatments to cancer patients.

Takeda's Acquisition Of GammaDelta Therapeutics Enhances Its Cell Therapy Portfolio

In October 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company specializing in drug development and commercialization, acquired GammaDelta Therapeutics Limited for undisclosed amount. Through this acquisition, Takeda will acquire early-stage cell therapy programmes in addition to GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, which encompass both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited is a UK-based biotechnology company specializing in the research and development of T-cell therapy and immunotherapy for cancer treatment. North America was the largest region in the cell therapy market in 2023. The regions covered in the cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell therapy market research report is one of a series of new reports from The Business Research Company that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Oligonucleotide Therapy Market Definition And Segments

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides' most popular application (polymerase chain reaction) The main types of oligonucleotide therapy are antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are synthetic DNA oligomers that hybridize to a target RNA in a sequence-specific manner. They’ve been used to successfully limit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. It is used in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and others, and is implemented in hospitals, and research institutes. The oligonucleotide therapy market covered in this report is segmented – 1) By Type: Antisense Oligonucleotide, Aptamer, Other Types 2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User 3) By End User: Hospitals, Research Institutes The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $4.9 billion in 2023 to $5.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction. The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $8.75 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

Increasing Cancer Epidemic Driving Growth In The Oligonucleotide Therapy Market

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the oligonucleotide therapy market over the forthcoming years.

Government-Led Healthcare Research And Development Initiatives A Boost For Oligonucleotide Therapy

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the oligonucleotide therapy market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Several government authorities are initiating various healthcare initiatives to support various aspects including oligonucleotide therapy. For instance, in 2022, according to the Department of Health and Social Care, a UK-based government authority, the UK government announced £260 million (US $270.65) million in funding to boost healthcare research and manufacturing. This was committed by BEIS and DHSC to support NHS-led health research into diagnostics and treatment through new privacy-preserving platforms and clinical research services, and £60 million (US $63.60 million) to help expand life sciences manufacturing in the UK. Major companies operating in the oligonucleotide therapy market report are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals PLC, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Pharmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.

FDA Approval Challenges Impede The Oligonucleotide Therapy Market's Growth

The FDA's low number of drug approvals hampered the oligonucleotide therapy market during the forecast period. For instance, according to the National Library of Medicine, a US-based government agency, in 2022, a total of 37 new drug entities were approved, but that year registered the lowest number of drug approvals since 2016. This can be attributed to the strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

Innovative Oligonucleotide Therapy Advancements Pioneering Patient-Centric Solutions

The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for the treatment of patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody targets SOD1 mRNA to reduce the synthesis of SOD1 protein

Elevating Pediatric Care Innovative Therapies In The Oligonucleotide Therapy Market

Major companies operating in oligonucleotide therapy market are introducing innovative therapies for pediatrics to drive the revenues in the market. Elevidys is the first and only gene therapy approved by the FDA for the treatment of Duchenne muscular dystrophy (DMD). For instance, in June 2023, the FDA approved Elevidys, a gene therapy for the treatment of pediatric patients of 4 through 5 years of age with Duchenne muscular dystrophy (DMD). While not specifically an oligonucleotide therapy, this approval highlights the advancements in gene-based treatments for genetic diseases.

Fostering Precision Medicine With Vanda Pharmaceuticals And Olipass Partnership To Advance Aso Therapeutics

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company and OliPass , a South Korea-based biotechnology company announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. The partnership aims to jointly develop a set of ASO molecules based on OliPass' proprietary modified peptide nucleic acids. The partnership leverages the respective strengths of Vanda and OliPass to support the development of ASO-based precision medicine therapeutics.. North America was the largest region in the oligonucleotide therapy market in 2023. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Enzymes Market Definition And Segments

Enzyme refers to a protein that almost usually serves as a biological catalyst. It accelerates a certain chemical reaction in the cell. It is a substance that serves as a catalyst in living things, controlling the speed at which chemical processes take place without undergoing any changes. The main product types of enzymes are asparaginase, lipase, protease, nattokinase, chitinase, serratiopeptidase, collagenase, ligase, and others. A protease is an enzyme that catalyzes proteolysis, which breaks proteins down into smaller polypeptides or single amino acids and promotes the formation of new protein products. The enzymes are used for the treatment of leukemia, stomach disorders, antitumor, skin ulcers, gauche disease, Fabry disease, and others and are used by drug manufacturers, hospitals, private clinics, and research laboratories. The enzymes market covered in this report is segmented – 1) By Product Type: Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products 2) By Application: Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications 3) By End User: Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories The enzymes market size has grown rapidly in recent years. It will grow from $11.78 billion in 2023 to $13.52 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to globalization and market expansion, research and development investments, consumer awareness and demand, bioprocessing technology improvements, waste reduction and recycling. The enzymes market size is expected to see rapid growth in the next few years. It will grow to $22.86 billion in 2028 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to market demand dynamics, focus on sustainable practices, health and nutrition trends, biofuel and renewable energy, emerging applications. Major trends in the forecast period include biotechnology advancements, sustainability demands, food and beverage industry demand, industrial applications expansion, consumer preference for natural products.

Enzyme Market Surges With The Growing Prevalence Of Digestive Disorders

The rise in prevalence of digestive disorders is expected to propel the growth of the enzyme market going forward. Digestive disorders are a group of health conditions that affect the digestive system. Some common digestive disorders include gastroesophageal reflux disease (GERD), cancer, irritable bowel syndrome (IBS), lactose intolerance, hiatal hernia, and gallstones. Digestive enzymes help break down food into smaller molecules that can be absorbed by the body. For instance, in October 2022, according to the National Center for Biotechnology Information (NCBI), a US-based resource for the scientific research community, the prevalence of irritable bowel syndrome (IBS) ranges between 10% and 15% in the United States and nearly 12% of patients seek medical care in primary care practices for IBS-related complaints. Thus, the rise in prevalence of digestive disorders is driving the growth of the enzyme market.

Unlocking The Potential Of Enzyme-Based Therapies In The Global Fight Against Cancer

The growing prevalence of cancer requiring drug-metabolizing enzymes (DMEs) for chemotherapy is expected to drive the growth of the enzyme market in the coming years. The activation of enzymes in the human body help destroy the cancer cells and breaks down the tumor. The expression and function of drug-metabolizing enzymes (DMEs) in cancer patients' tumor tissues and metabolic organs is therefore essential and help patients for whom reaction to anticancer drugs and response to chemotherapy is low. For instance, according to the Cancer Facts and Figures 2022 report published by the American Cancer Society, a US-based professional organization company, there will be an estimated 1.9 million new cancer cases diagnosed in the United States in 2022. This is an increase from the 1.8 million new cancer cases reported in 2020. However, the estimated number of cancer deaths in 2022 is slightly higher than in 2021, with 609,360 cancer deaths projected in 2022 compared to 608,570 in 2021. Therefore, the increasing prevalence of cancer that can be cured using therapeutic enzymes is predicted to drive the enzyme market growth. Major companies operating in the enzymes market report are Ramboll Group A/S, Jacobs Engineering Group Inc., AECOM Technical Services Inc., ERM Group Limited, WSP Global Inc., SNC-Lavalin Group Inc., Wood PLC, Stantec Inc., Black & Veatch Corporation, Tetra Tech Inc., Arcadis NV, Mott MacDonald Group Ltd., GHD Group Limited, TRC Companies Inc., Form Technologies Inc., Golder Associates Ltd., Cardno Limited, CH2M HILL Engineers Inc., SLR Consulting Ltd., Weston Solutions Inc., IndustrySafe Inc., ECS Limited, Geosyntec Consultants LLC, Apex Companies Inc., GZA GeoEnvironmental Technologies Inc., Haley & Aldrich Inc., Intelex Corporation, iAuditor Inc., Metrix Software Solutions Inc., Lighthouse Systems Inc., SafetyTek Inc., Strategix Application Solutions LLC, Effivity Technologies LLC, SiteDocs Inc., SafetySync LLC, Qooling Systems Inc.

Innovative Enzyme-Based Medications Transforming Treatment For Rare Genetic Disorders

Major companies operating in the enzyme market are developing innovative products such as Lamzede to better serve patients. Lamzede (velmanase alfa) is a medication used for the treatment of alpha-mannosidosis, a rare genetic disorder caused by deficient activity of the lysosomal alpha-galactosidase-A enzyme. For instance, in May 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical manufacturing company received FDA approval for Lamzede (velmanase alfa) for the treatment of non-neurological symptoms of patients with mild-to-moderate alpha-mannosidosis. Lamzede is a recombinant form of human alpha-mannosidase developed in mammalian Chinese hamster ovary (CHO) cells using recombinant DNA technology. It is the first enzyme replacement therapy approved in the U.S. for the treatment of the non-central nervous system manifestations of alpha-mannosidosis.

Enzyme Therapies For Cancer And Rare Genetic Disorders

The development of new approaches to treat cancer using enzymes is a key trend gaining popularity in the enzymes market. Major universities and companies are investing in research focusing on evolving new solutions in enzyme therapies for cancer treatment. For instance, in May 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical manufacturing company received FDA approval for ELFABRIO (pegunigalsidase alfa-iwxj) to treat Fabry disease, a rare genetic disorder caused by deficient activity of the lysosomal a-galactosidase-A enzyme, which leads to progressive buildup of globotriaosylceramide (Gb3) in blood vessel walls throughout the body. ELFABRIO (pegunigalsidase alfa-iwxj) is a PEGylated enzyme replacement therapy (ERT).

AstraZeneca Expands Cardiorenal Portfolio With Acquisition Of Cincor Pharma Inc

In February 2023, AstraZeneca, a US-based pharmaceutical company acquired CinCor Pharma Inc. for $1.3 billion. The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based biotechnology company developing enzyme-based therapeutics. North America was the largest region in the enzymes market in 2023. The regions covered in the enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The enzyme market consists of sales of oxidoreductases, transferases, and hydrolases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The enzymes market research report is one of a series of new reports from The Business Research Company that provides enzymes market statistics, including enzymes industry global market size, regional shares, competitors with an enzymes market share, detailed enzymes market segments, market trends, and opportunities, and any further data you may need to thrive in the enzymes industry. This enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biosimilars Market Definition And Segments

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs. The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others. The biosimilars market covered in this report is segmented – 1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others 2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins 3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications The biosimilars market size has grown rapidly in recent years. It will grow from $15.86 billion in 2023 to $18.85 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, a strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration. The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $35.81 billion in 2028 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Major trends in the forecast period include a focus on robust R&D activities for the development of effective and innovative drugs, on focus on M&A growth strategies, a focus on establishing strategic partnerships, a focus on increasing investments, and a focus on artificial intelligence.

Rising Prevalence Of Chronic Diseases Sparks Growth In The Biosimilars Market

The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.

Rising Healthcare Expenditures Fueling Growth In The Biosimilars Market

The increasing healthcare expenditures are expected to propel the growth of the biosimilars market going forward. Healthcare expenditures refer to the total spending on healthcare goods and services within a given population or healthcare system. The biosimilar market helps reduce healthcare expenditures by offering more cost-effective alternatives to expensive biologic drugs, thereby lowering treatment costs for patients and healthcare systems. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2020 and 2021, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms. Therefore, increasing healthcare expenditures are driving the growth of the biosimilars market. Major companies operating in the biosimilars market report are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Biocon, Celltrion, Inc., Coherus Biosciences, Elli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd., Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd., Apotex Pty Ltd., Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, HARMONIE MEDICAL SERVICE Saint-Benoît, INSULET FRANCE SAS Paris, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Low Physician Awareness Hinders Biosimilars Market Growth

The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the biosimilars market.

Innovative Product Launched Enhance Biosimilars Market

Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge in the market. AMJEVITA is the first U.S. biosimilar to Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases. For instance, in January 2023, Amgen Inc., a US-based biotechnology company, launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now available in the US. AMJEVITA (40 mg) is available at a list price (wholesale acquisition cost) 55% below the current Humira list price. AMJEVITA is also available at a list price 5% below the current Humira list price.

Innovative Biosimilar FYLNETRA By Amneal Pharmaceuticals Targets Neutropenia In Cancer Patients

Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge in the market. FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. For instance, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, launched the commercial launch of FYLNETRA (pegfilgrastim-pbbk), a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia (low neutrophils, which are a type of white blood cells that fight infection), which is commonly experienced by patients undergoing chemotherapy.

Biocon Biologics Ltd. Acquisition Of Viatris Inc. Biosimilars Business

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. The acquisition brings Biocon Biologics closer to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and numerous emerging regions. In numerous emerging market positions, the merger of Viatris' acquired worldwide biosimilars company with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization Viatris Inc. is a US-based pharmaceutical company that develops, licenses, manufactures, markets, and distributes generic and branded medicines. North America was the largest region in the global biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Pediatric Vaccine Market Definition And Segments

Pediatric vaccines refer to medications that are typically given to children as a form of protection against serious, frequently fatal diseases. They get the children’s body ready to battle the disease more quickly and successfully by boosting its natural defenses. The main types of pediatric vaccines are monovalent and multivalent. A monovalent vaccine is made up of only one antigen strain. The technology used includes live attenuated, inactivated, toxoid, conjugate, and other technologies to provide immunity from infectious disease, allergy, and cancer. The pediatric vaccine market covered in this report is segmented – 1) By Vaccine Type: Monovalent, Multivalent 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies 3) By Application: Infectious Disease, Allergy, Cancer The pediatric vaccine market size has grown strongly in recent years. It will grow from $49.89 billion in 2023 to $53.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased prevalence of chronic diseases, immunization policies to eradicate endemic diseases, increased funding for vaccine development. The pediatric vaccine market size is expected to see rapid growth in the next few years. It will grow to $83.49 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing cases of invasive cervical cancer, strong late-stage pipeline and new drug approvals, increasing prevalence of infectious diseases. Major trends in the forecast period include developing combination vaccines to meet market demand, consider investing R&D activities for the development of effective vaccines, focusing on developing live attenuated vaccines, utilizing new immune engineering and advance delivery systems and implementing artificial intelligence (AI) in vaccine development to simplify the process and make manufacturing easy.

Growing Prevalence Of Chronic Diseases In Children Boosts Pediatric Vaccine Market

The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. in March 2022, according to the Australian Bureau of Statistics, an Australia-based self-governing statutory body entrusted with gathering and evaluating data and providing factual recommendations, about half of the overall population (46.6%, or 11.6 million) had at least one chronic condition. The increased prevalence of chronic diseases among children rises the demand for immunization from chronic diseases, hence, driving the growth of the pediatric vaccine market.

Rising Prevalence Of Pediatric Diseases Drives Growth In The Pediatric Vaccine Market

The increasing prevalence of pediatric diseases is expected to propel the growth of the pediatric vaccine market in the coming years. Pediatric diseases are disorders that afflict children between the ages of infancy and puberty. These disorders can be moderate to severe, and they can be either chronic or acute. Pediatric vaccinations are critical to the prevention and control of a wide spectrum of pediatric disorders. They are given to newborns and children to protect them from numerous infectious illnesses. For instance, in April 2023, according to Asthma + Lung UK, a UK-based non-profit group dedicated to preserving the right to breathe, in England and Wales, hospital stays for kids with asthma increased by 149% between 2021 and 2022. During 2020 and 2021, 19,506 children were hospitalized with asthma symptoms, compared to 7,850 during the years 2020 and 2021. Therefore, the increasing prevalence of pediatric diseases is driving the pediatric vaccine market. Major companies operating in the pediatric vaccine market report are Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Sanofi SA, Pfizer Inc., AstraZeneca, GlaxoSmithKline PLC, Sinovac Biotech Ltd., Zydus Cadila, Indian Immunologicals Limited, Panacea Biotec, Takeda Pharmaceutical Company, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, CSL Limited, BIO-MED, Sun Pharmaceutical Industries Ltd., Sinopharm, Walvax biotechnology, Fosun Pharma, BioNTech, MCM Vaccine Company, Seqirus, Roche, Johnson & Johnson, Novartis, Connaught Laboratories, Inc., Wyeth-Ayerst, Grifols, Ataulfo de Paiva Foundation, Bio-Manguinhos–Institute of Technology on Immunobiologicals, Butantan Institute, Ezequiel Dias Foundation (FUNED), Sinergium

Vaccine Hesitancy Among Parents Poses Challenges For Pediatric Vaccine Market

Vaccine refusal by parents for their children is a prevailing tradition in many countries. Among the reasons for withholding children from vaccination are lack of knowledge, religious and philosophical objections, exaggerated concerns regarding vaccine safety, and others. According to a nationwide survey found that over half (51%) of pediatric services in the United States have a policy to dismiss families that refuse childhood vaccines. 37% of pediatricians themselves said they often dismissed families for refusing vaccines, and 6% said they would dismiss a family for choosing to reach out to crucial early vaccines. Governments are imposing laws and organizing awareness programs to overcome parents’ and families’ resistance to the child’s vaccine, but are unable to impose any strict rules against parents’ refusal of children’s immunization, which may hinder the pediatric vaccines market growth.

Growing Demand For Novel Vaccines Drives Innovation In Pediatric Vaccine Market

The demand for novel vaccines is steadily growing to deliver improved immunization against challenging infectious diseases (e.g., tuberculosis, HIV/ AIDS) and non-communicable chronic diseases such as cancer and neurodegenerative diseases. Novel approaches to vaccine development include structural immunogenic design, gene-based vaccine platforms, and effective adjuvant recombinant antigen formulations. To meet the increasing demand for novel vaccines, there is a continuous quest for pediatric vaccine manufacturers and developers for the innovation of vaccine design and manufacturing technologies. For instance, in April 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company announced the U.S. FDA approval of REVNAR 20, a 20-valent Pneumococcal Conjugate Vaccine for children and infants.

Recent FDA Approval Of Vaccine Marks A Milestone In Pediatric Immunization

Major companies operating in the pediatric vaccine market are focusing on product approvals to better meet the needs of their existing consumers. ABRYSVO is a vaccine authorized by the FDA for use in pregnant women for the prevention of lower respiratory tract disease (LRTD) and severe LRTD triggered by respiratory syncytial virus (RSV) in children till 6 months of age. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company announced the U.S. FDA approval of Pfizer's ABRYSVO vaccine for the Avoidance of Respiratory Syncytial Virus (RSV) in Infants by active immunization of pregnant women 32-36 weeks gestational age. The first and only maternal vaccination approved in the United States to help prevent newborns against lower respiratory tract illness (LRTD) and severe LRTD caused by RSV from birth to six months of age. North America was the largest region in the pediatric vaccine market in 2023. Middle East is expected to be the largest growing region in the global pediatric vaccine market share during the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the pediatric vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The pediatric vaccine market consists of sales of BCG vaccines, hepatitis B vaccines, pentavalent vaccines, and rotavirus vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The pediatric vaccine market research report is one of a series of new reports from The Business Research Company that provides pediatric vaccine market statistics, including pediatric vaccines industry global market size, regional shares, competitors with a pediatric vaccine market share, detailed pediatric vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric vaccine industry. This pediatric vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Antisense & RNAi Therapeutics Market Definition And Segments

Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs. The main technologies of antisense & RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates protein-coding gene expression. The various routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other delivery methods that are used for the indication of oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, other. The antisense & RNAi therapeutics market covered in this report is segmented – 1) By Technology: RNA Interference, Antisense RNA 2) By Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications The antisense & RNAi therapeutics market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to a rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets. The antisense & RNAi therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to an increase in healthcare access, rising prevalence of cancer, and increasing demand for antisense and RNAi therapeutics due to COVID-19. Major trends in the forecast period include focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, development of new and improved antisense and RNAi therapeutics, and collaboration with other companies for product innovation and to drive revenues.

Emerging Demand Antisense & RNAI Therapeutics For Neurodegenerative Disorders And Infectious Diseases

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases affecting millions of people globally. In the USA, 6.2 million people may have Alzheimer’s disease. As per January 2023 data approximately 500,000 people in the USA are diagnosed with Parkinson’s disease. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.

Impact Of Chronic Diseases Fueling The Antisense & RNAi Therapeutics Market

The rising prevalence of chronic diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. A chronic disease is a long-term health condition that cannot be cured. It includes diseases such as cardiovascular diseases, oncological disorders, and others. Antisense and RNA interference (RNAi) therapeutics have shown potential in the treatment of various cardiovascular diseases by targeting specific genes or molecular pathways associated with the pathogenesis of these conditions. For instance, according to the World Heart Report 2023, published by the World Health Organization (WHO) a US-based specialized agency, in the year 2021, approximately 20.5 million individuals succumbed to a cardiovascular condition, representing roughly one-third of all global deaths as of 2021. Hence, the growing prevalence of chronic diseases is expected to drive the growth of the antisense & RNAi therapeutics market. Major companies operating in the antisense & RNAi therapeutics market report are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd., Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline PLC, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc., Calando Pharmaceuticals, Enzon Pharmaceuticals Inc., Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

Financial Hurdles The Impact Of High Costs On The Antisense & RNAI Therapeutics Market

The high cost of RNA interference-based drugs is expected to act as a major restraint on the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, a long product approval process, high development cost, and a comparably small number of patients are a few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics market growth in upcoming years.

Strategic Collaborations Driving Innovation In The Antisense & RNAI Therapeutics Market

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives, such as collaborations and partnerships to sustain in the increasingly competitive market. Strategic collaboration is a business strategy that involves two or more companies working together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company offering services for the discovery of peptides, partnered with SanegeneBio Inc., a UK-based company involved in the developing novel RNAi-based medicines for the identification of tissue-specific delivery of RNA therapeutics for efficient gene knockdown, aiming to develop a portfolio of advanced RNAi therapeutics. The collaboration encompasses hit identification and cell-based internalization studies, with Sanegene having the option to further develop the hits derived from the screening activities, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Orbit Discovery's unique peptide display engine enables the screening of large peptide libraries, offering faster discovery times for relevant peptide leads based on affinity and functional screens.

GlaxoSmithKline (GSK) And Wave Life Sciences Joint Venture For Oligonucleotide Therapeutics

Major companies operating in the antisense & RNAi therapeutics market are undergoing partnerships to develop a new relationship in which two or more organizations develop innovative products. A strategic collaboration is a cooperative partnership between two or more organizations, with complementary strengths or resources, to achieve common goals or objectives. For instance, in December 2022, GlaxoSmithKline (GSK), a UK-based pharmaceutical company, and Wave Life Sciences, a US-based genetic medicines company, announced a collaboration to develop oligonucleotide therapeutics, focusing on novel genetic targets. This strategic partnership combines GSK's expertise in genetics with Wave's PRISM platform, aiming to advance up to eight preclinical programs. Additionally, GSK receives an exclusive global license for Wave's WVE-006, a potential first-in-class RNA editing program targeting alpha-1 antitrypsin deficiency (AATD). Wave's PRISM platform uniquely offers three RNA-targeting modalities, incorporating novel chemistry to optimize therapeutic oligonucleotides' properties.

AstraZeneca And Ionis Pharmaceuticals Strategic Partnership For Eplontersen Development

In December 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, announced a strategic partnership with Ionis Pharmaceuticals Inc. for an undisclosed sum. Under this strategic partnership, Eplontersen will be developed and commercialized by the two businesses together in the US and by AstraZeneca in all other regions outside of Latin America. Ionis Pharmaceuticals Inc. is a US-based biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics and drugs North America was the largest region in the antisense & RNAi therapeutics market in 2023. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antisense & RNAi therapeutics market research report is one of a series of new reports from The Business Research Company that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Bi-Specific MAbs Market Definition And Segments

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy. The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others. The bi-specific MAbs market covered in this report is segmented – 1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab 2) By Product Type: In Vivo, In Vitro 3) By Indication: Cancer, Hemophilia A, Ophthalmic 4) By End Use: Hospitals, Research Institutes, Other End-Users The bi-specific MAbs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding, and government initiatives. The bi-specific MAbs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population, and an increase in the prevalence of chronic diseases. Major trends in the forecast period include a focus on technological advancements, product innovation, a focus on artificial intelligence, investment in targeted and combination therapy, and strategic partnerships.

Impact Of Increasing Cancer Prevalence On The Bi-Specific MAbs Market

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer-related deaths in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.

Government Support In Healthcare Research And Development Boosting The Bi-Specific MAbs Market

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the Bi-Specific MAbs market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities to address specific issues, achieve certain goals, or create positive changes in society. For Instance, in August 2023, The Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) collaborated with Regeneron Pharmaceuticals Inc., a US-based science and technology company for the development of a next-generation monoclonal antibody therapy for the prevention of SARS-CoV-2 infection as part of the U.S. Department of Health and Human Services' 'Project NextGen.' The agreement entails up to 70% of funding from the U.S. government for Regeneron's costs in clinical development activities for the monoclonal antibody therapy, with an estimated contract value of approximately $326 million. Therefore, the government initiatives for research and development in healthcare drive the Bi-Specific MAbs market. Major companies operating in the bi-specific MAbs market report are F. Hoffmann-La Roche AG, Amgen Inc., Johnson & Johnson, Innovent Biologics, Sino Biological Inc., Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, EpimAb Biotherapeutics, Merck & Co Inc., Eli Lilly Company Inc., AbbVie Inc., Bayer AG, Pfizer Inc., Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd., Baxter International, Cipla Medpro South Africa

Growing Popularity Of Alternative Cancer Therapies Implications For The Bi-Specific MAbs Market

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographispaniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales and hence impacts the bi-specific MAbs market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market shortly.

Strategic Collaborations And Partnerships Fuel Growth In The Bi-Specific MAbs Market

Companies in the bi-specific MAbs market are increasingly investing in various strategic initiatives, such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. A strategic collaboration is a cooperative partnership between two or more organizations to achieve common goals or objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical company, and MacroGenics, a US-based biopharmaceutical company, entered into an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3 using MacroGenics' DART platform, along with two other bispecific research programs. The collaboration grants Gilead an exclusive option to license MGD024, which has the potential to treat various hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to minimize cytokine-release syndrome (CRS) and allow intermittent dosing, potentially leading to more patient-friendly treatment and improved clinical outcomes for individuals with AML and MDS.

Advanced Technologies Transforming The Bi-Specific MAbs Market

Major companies operating in the Bi-Specific MAbs market are introducing advanced technologies such as bispecific monoclonal antibodies to gain a competitive edge in the market. Bi-specific monoclonal Antibodies (MAbs) are a type of artificial protein that can simultaneously bind to two different types of antigens. These antibodies are designed to target specific molecules present on the surface of cells. For instance, in September 2021, Amgen, a US-based biopharmaceutical company, and Boehringer Ingelheim, a Germany-based pharmaceutical company are collaborating on a Phase II-ready project. Convincing clinicians to transition between bispecific MAbs would necessitate significant improvements in efficacy or safety. Alternative strategies, such as initiating treatment at an earlier stage, modifying the administration method, or adjusting the treatment frequency, are feasible but demand timely strategic planning from the developers. Bispecific mAb is poised not only to outperform its competitors but also to potentially encroach upon the market share of CAR-T cell therapies in the relapsed or refractory multiple myeloma sector.

Takeda's Strategic Acquisition: Expanding Bispecific Antibody Technology

In March 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company acquired Maverick Therapeutics for an undisclosed amount. With this acquisition, Takeda aims at developing bispecific antibody technology and patients would benefit from the expansion of resources and experience and accelerate development of our T-cell engager platform and pipeline of innovative bispecific immunotherapies. Maverick Therapeutics is a US-based company that offers biospecific MAbs. North America was the largest region in the bi-specific MAbs market in 2023. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the bi-specific MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.